Uso Compassionevole (Italy): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What Uso Compassionevole is
Origin and authorising body. Italy, under Decreto Ministeriale 7 settembre 2017 regulating compassionate use of medicines. The authorising body for each individual case is the Agenzia Italiana del Farmaco (AIFA), with regional health authority (Azienda Sanitaria Locale, ASL) and hospital ethics committee oversight, acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Decreto Ministeriale 7 settembre 2017 regulates compassionate use in Italy, replacing the prior 2003 framework. The decree distinguishes between three categories: nominative compassionate use (individual patient), cohort compassionate use (defined patient group under a single protocol), and use of a medicine that is the subject of an ongoing clinical trial. Law 648/1996 provides a separate framework (Legge 648) for off-label use of medicines that are authorised in another country but not in Italy.
Uso Compassionevole (Italy) is the Italian framework for compassionate use of medicines in clinical development. The cohort and nominative tracks differ in documentation depth and review timeline. The framework is widely used for oncology and rare-disease agents in late-Phase 3 development. Italy also operates Legge 648 for medicines authorised abroad but not in Italy, which functions as a hybrid named-patient and off-label-use mechanism for medicines approved by major foreign regulators (FDA, MHRA, Health Canada).
Italian compassionate-use applications are filed with AIFA and reviewed centrally. Dispensing operates through hospital pharmacies under regional ASL oversight. The treating hospital's ethics committee reviews the application alongside AIFA. Once authorised, the medicine is dispensed through the hospital pharmacy. Major Italian centres handling the largest case volumes include Istituto Europeo di Oncologia Milan, Istituto Nazionale Tumori Milan, Ospedale Pediatrico Bambino Gesu Rome, Policlinico Umberto I Rome, AOU Federico II Naples, and AOU Citta della Salute Turin.
This page consolidates Reserve Meds's operational view of the Uso Compassionevole (Italy) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Uso Compassionevole (Italy)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use Uso Compassionevole
Uso Compassionevole is used by hospital-affiliated Italian physicians on behalf of patients with serious or life-threatening conditions. The framework is well used in Italian academic medicine. Cross-border patients cannot directly use the Italian framework; the existence of an AIFA authorisation is a useful regulatory precedent for destination-country regulators.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under Uso Compassionevole
Specialty oncology agents (immune checkpoint inhibitors, CAR-T agents, ADCs in pre-Italian registration), rare-disease biologics, advanced therapy medicinal products, paediatric extensions of adult-approved medicines, and post-approval indications not yet through Italian registration.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Uso Compassionevole (Italy) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Uso Compassionevole (Italy) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Uso Compassionevole (Italy) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Uso Compassionevole (Italy) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Uso Compassionevole (Italy) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Indirect (reference precedent only) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Indirect (reference precedent only) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Indirect (reference precedent only) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Indirect (reference precedent only) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Indirect (reference precedent only) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Indirect (reference precedent only) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Indirect (reference precedent only) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Indirect (reference precedent only) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Indirect (reference precedent only) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Indirect (reference precedent only) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Uso Compassionevole (Italy) authorisation as the legal basis for import but does recognise a Uso Compassionevole (Italy) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A Uso Compassionevole application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- Treating physician's clinical justification.
- Patient clinical history and informed consent.
- Hospital ethics committee approval (Comitato Etico).
- Manufacturer letter confirming supply.
- Pharmacy dispensing plan.
- Periodic safety and outcomes reporting per the decree.
- Legge 648 application where the framework applies for foreign-approved medicines.
Typical timeline
AIFA routine review: 3 to 5 weeks for individual nominative cases, 8 to 16 weeks for new cohort protocols. Legge 648 imports: 4 to 6 weeks. Cross-border patients using parallel home-country frameworks complete in 4 to 8 weeks end-to-end.
Costs and reimbursement
Italian reimbursement through the Servizio Sanitario Nazionale may cover compassionate-use medicines depending on indication; this is decided regionally. Cross-border patients pay the relevant per-country acquisition cost plus logistics, customs, dispensing, and coordinator fees.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Uso Compassionevole (Italy) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Uso Compassionevole (Italy) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.